RxDoctor Payments Data

Joseph Kamerling, MD

Ophthalmology · Barrington, NJNPI 1972591634

Payments from drug & device makers

$785in general payments, 2019–2025

Across 46 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$235
  • AbbVie$165
  • Bausch & Lomb Americas Inc.$87
  • Sun Pharmaceutical Industries Inc.$75
  • Novartis$67
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$40
  • plus $116 from 6 others

What the payments were for

  • Food & beverage$74895%
  • Gifts$375%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$785 in reported general payments places this provider in the 35th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$127,518
Medicare patients
438
Services billed
1,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine64$99,035
LumiganBimatoprost99$56,249
VyzultaLatanoprostene Bunod103$54,701
TyrvayaVarenicline Tartrate19$25,940
CequaCyclosporine14$17,648
SimbrinzaBrinzolamide/Brimonidine Tart46$14,283
MieboPerfluorohexyloctane/Pf18$13,373
Travoprost52$10,163
Cyclosporine14$9,901
RocklatanNetarsudil Mesylat/Latanoprost18$9,452
Brimonidine Tartrate46$7,323
Latanoprost245$3,278
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,704
Prednisolone Acetate33$1,386
Timolol Maleate36$755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$165$155,284163 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo$87$68,074121 claims
Oyster Point Pharma, Inc.Tyrvaya$235$25,94019 claims
Sun Pharmaceutical Industries Inc.Cequa$75$17,64814 claims
Aerie Pharmaceuticals, Inc.Rocklatan$14$9,45218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Barrington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →